« PhRMA Fires Back at AARP Report | Main | Pharma News from India »

08/26/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133f357a279970b

Listed below are links to weblogs that reference Senators Ask Why Provenge Being Reviewed for On-Label Use?:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

It may be a good question but as Adam Feuerstein reports today (Sept 27th) in The Street - Medicare's questions are stirring investor fears and Dendron's stock is going down
http://www.thestreet.com/story/10872332/1/dendreon-shares-roiled-by-medicare-questions.html

bigredbruce

WSJ Health blog reports (Sept 1st) that Dendreon shares are up based on news of CMS scheduling meeting to review Provenge
http://blogs.wsj.com/health/2010/09/01/dendreon-shares-up-on-provenge-medicare-coverage-meeting-scheduling/

bigredbruce

Another update on this story from the Pharmalot blog (Sept 1st)
http://www.pharmalot.com/2010/09/cms-will-hold-a-meeting-to-review-provenge/

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada